Lynda Charters Enoch started her early “eye life” at the Schepens Eye Research Institute, Boston, which ultimately culminated in her current position as an Editor of Ophthalmology Times.
AAO 2020: Micro Vacuum Pick for use during vitreoretinal surgery proving to be a better mousetrap
November 13th 2020During Day 1 of AAO 2020, Carl Awh, MD, discusses the Micro-Vacuum Pick, a device for peeling internal limiting membranes that's providing vitreoretinal surgeons an alternative to forceps during surgeries.
Read More
Study examines silicone rubber balloon scleral buckling for RRDs
October 23rd 2020Silicone rubber balloon scleral buckling is a novel alternative to the current extraocular procedures for treating simple rhegmatogenous retinal detachments. Investigators have found that this surgery may be a novel alternative to the current extraocular procedures for simple RRD.
Read More
Infiltrative optic neuropathy in a patient with esophageal adenocarcinoma
October 4th 2020Dr M.M. Alberto Pestano explains how optic neuropathy can present as a masquerade syndrome. He highlighted a case of unilateral infiltrative optic neuropathy that presented as a masquerade syndrome in a man with esophageal adenocarcinoma.
Read More
Port Delivery System with ranibizumab: Maintenance of vision with reduced treatment burden
October 3rd 2020A port delivery system with ranibizumab with dosing every 24 weeks has been shown in a Phase III trial to be equivalent to monthly intravitreal ranibizumab injection to treat neovascular age-related macular degeneration, according to Dr Carl Regillo, who reported on behalf of the Archway Trial investigators.
Read More
OCTA: Why the jury may still be out
September 11th 2020Though OCTA has become indispensable for managing macular degeneration and diabetic retinopathy, Robert L. Stamper, MD, explains why the technology must become more sophisticated and evolved before it reaches its full potential for glaucoma specialists.
Read More
ASRS 2020: PDS with ranibizumab signals paradigm shift in treatment of neovascular AMD
July 27th 2020PDS with ranibizumab is proving to be an innovation solution for nAMD patients. Peter Campochiaro, MD, detailed findings of phase 2 of the Ladder Trial and ongoing Archway Trial during the virtual 2020 ASRS annual meeting.
Read More
ASRS 2020: Protocol T Extension Study shows long-term visual declines in DME eyes
July 27th 2020The results of the Protocol T Extension Study underscore the need for methods to improve long-term visual gains in eyes with diabetic macular edema, according to Dante Pieramici, MD, on behalf of the DRCR Retina Network, during the American Society of Retina Specialists 2020 Virtual Annual Meeting.
Read More
Evaluating the change in VA, CMT after early switch of anti-VEGF drugs
July 22nd 2020The study authors hypothesized that patients poorly responding to ranibizumab may have resulted from tachyphylaxis or tolerance to the drug and regarding the nonresponders, they speculated that VEGF-A may not have been the main cause of the neovascular growth.
Read More